Reviewing BioLargo (BLGO) and Its Peers

BioLargo (NASDAQ:BLGO) is one of 32 public companies in the “Chemicals & allied products” industry, but how does it compare to its peers? We will compare BioLargo to similar businesses based on the strength of its dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.

Volatility & Risk

BioLargo has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.81, meaning that their average stock price is 81% more volatile than the S&P 500.

Valuation & Earnings

This table compares BioLargo and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.16
BioLargo Competitors	$6.84 billion	$211.64 million	69.50

BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BioLargo and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1251	1567	44	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 13.55%. Given BioLargo’s peers higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its peers.

Profitability

This table compares BioLargo and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-591.84%	5.15%	-0.65%

Insider and Institutional Ownership

0.0% of BioLargo shares are held by institutional investors. Comparatively, 70.6% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by insiders. Comparatively, 10.6% of shares of all “Chemicals & allied products” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BioLargo peers beat BioLargo on 8 of the 10 factors compared.

About BioLargo

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.